Aspirin in Primary Prevention: Needs Individual Clinical Judgments - 23/07/20

Doi : 10.1016/j.amjmed.2020.01.006

Alexander Gitin, BS ^a, Marc A. Pfeffer, MD, PhD ^b, David L. DeMets, PhD ^c, Charles H. Hennekens, MD, DrPH ^d,^⁎
^a First-year medical student University of Florida College of Medicine Gainesville
^b Department of Medicine Harvard Medical School and Brigham and Women's Hospital Boston
^c Department of Biostatistics and Informatics University of Wisconsin School of Medicine & Public Health Madison
^d Charles E. Schmidt College of Medicine Florida Atlantic University Boca Raton

^⁎Requests for reprints should be addressed to Charles H. Hennekens, MD, DrPH, Charles E. Schmidt College of Medicine, Florida Atlantic University, 2800 S. Ocean Blvd. PHA, Boca Raton, FL 33432.Charles E. Schmidt College of MedicineFlorida Atlantic University2800 S. Ocean Blvd. PHABoca RatonFL33432

El texto completo de este artículo está disponible en PDF.

	Funding: None.
	Conflict of Interest: AG reports no disclosures. MAP reports that he receives research support from Novartis. He serves as an independent scientist in an advisory role to AstraZeneca, Corvidia, DalCor, GlaxoSmithKline, Innovative Science Solutions, Jazz, MyoKardia, Novartis, Novo Nordisk, Pharmascience, Sanofi and Takeda; and has equity in DalCor. DLD reports that that he serves as an independent scientist in an advisory role to the National Institutes of Health, the Food and Drug Administration, and the pharmaceutical and medical device industry on the design, monitoring, and analysis of trials. He serves on data monitoring committees for Astra Zeneca, Amgen, Action, GSK, Merck, Sanofi, Boehringer Ingelheim, Teva, and Abbvie. He holds no stock in any pharmaceutical or device company. CHH reports that he serves as an independent scientist in an advisory role to investigators and sponsors as Chair of data monitoring committees for Amgen, British Heart Foundation, Cadila, Canadian Institutes of Health Research, DalCor, and Regeneron; to the US Food and Drug Administration, and UpToDate; receives royalties for authorship or editorship of 3 textbooks and as co-inventor on patents for inflammatory markers and cardiovascular disease that are held by Brigham and Women's Hospital; has an investment management relationship with the West-Bacon Group within SunTrust Investment Services, which has discretionary investment authority; does not own any common or preferred stock in any pharmaceutical or medical device company.
	Authorship: All authors had access to the data and a role in writing the manuscript.